skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Carvedilol in the treatment of chronic heart failure: Lessons from The Carvedilol Or Metoprolol European Trial

(2702) Views  (611) Full article downloads

Authors: Britt Kveiborg, Atheline Major-Petersen, Buris Christiansen, Christian Torp-Pedersen

Published Date May 2007 Volume 2007:3(1) Pages 31 - 37
DOI: http://dx.doi.org/10.2147/VHRM.S

Britt Kveiborg, Atheline Major-Petersen, Buris Christiansen, Christian Torp-Pedersen

Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark

Abstract: Beta-blockers have been shown to improve survival in patients with chronic heart failure. The effect of different generations of beta blockers has been debated. Both metoprolol and carvedilol have demonstrated beneficial effects in placebo-controlled trials. In The Carvedilol Or Metoprolol European Trial (COMET) two beta blockers were compared in a double-blind randomized matter. This is the first direct comparison between metoprolol and carvedilol of long-term effect on survival in patients with chronic heart failure. The all-cause mortality was significantly reduced in the favour of carvedilol. The dose and formulation of metoprolol used in this trial has caused debate, and it has been questioned whether a similar beta1-blockade is obtained in the two intervention groups. At this time there is an unresolved debate as to whether carvedilol is a superior beta-blocker or whether differences in beta1- blockade explained the results of COMET.

Keywords: beta-blockers, chronic heart failure, carvedilol








Readers of this article also read:

Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Editorial
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
Survey of a community-based infusion program for Australian patients with rheumatoid arthritis requiring treatment with tocilizumab: patient characteristics and drivers of patient satisfaction and patient-perceived benefits and concerns
Preventing stroke in atrial fibrillation patients – clinical utility of oral anticoagulants
Liraglutide therapy beyond glycemic control: An observational study in Indian patients with type 2 diabetes in real world setting
The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University